<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2016-10-17" updated="2019-12-24">
  <drugbank-id primary="true">DB11644</drugbank-id>
  <name>Tafamidis</name>
  <description>Tafamidis is a novel specific transthyretin (TTR) stabilizer or dissociation inhibitor. TTR ordinarily assumes a tetramer configuration that primarily serves to transport retinol-binding protein-vitamin A complex as well as thyroxine (to a small degree) in the blood. In TTR-related disorders such as TTR familial amyloid polyneuropathy (TTR-FAP), tetramer dissociation is accelerated and results in unregulated amyloidogenesis and amyloid fibril formation. The unwanted deposition of such formations in various tissues eventually contributes to the failure of autonomic and peripheral nervous system functions.&#13;
&#13;
Tafamidis was approved by the European Medicines Agency (EMA) in 2011 under the market name Vyndaqel for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP) in adult patients with early-stage symptomatic polyneuropathy to delay peripheral neurologic impairment. In June 2017, Pfizer received FDA Fast Track Designation for tafamidis which was later approved in May, 2019 for use in the treatment of cardiomyopathy in wild type or hereditary transthyretin-mediated amyloidosis.&#13;
&#13;
Tafamidis was developed by Jeffery W. Kelly in the company FoldRx that he had co-founded with Susan Lindquist of MIT and the Whitehead Institute.</description>
  <cas-number>594839-88-0</cas-number>
  <unii>8FG9H9D31J</unii>
  <average-mass>308.116</average-mass>
  <monoisotopic-mass>306.980298509</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A27205</ref-id>
        <pubmed-id>25022953</pubmed-id>
        <citation>Scott LJ: Tafamidis: a review of its use in familial amyloid polyneuropathy. Drugs. 2014 Aug;74(12):1371-8. doi: 10.1007/s40265-014-0260-2.</citation>
      </article>
      <article>
        <ref-id>A27206</ref-id>
        <pubmed-id>26894299</pubmed-id>
        <citation>Coelho T, Merlini G, Bulawa CE, Fleming JA, Judge DP, Kelly JW, Maurer MS, Plante-Bordeneuve V, Labaudiniere R, Mundayat R, Riley S, Lombardo I, Huertas P: Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurol Ther. 2016 Jun;5(1):1-25. doi: 10.1007/s40120-016-0040-x. Epub 2016 Feb 19.</citation>
      </article>
      <article>
        <ref-id>A32598</ref-id>
        <pubmed-id>17897357</pubmed-id>
        <citation>Fleming CE, Saraiva MJ, Sousa MM: Transthyretin enhances nerve regeneration. J Neurochem. 2007 Oct;103(2):831-9. doi: 10.1111/j.1471-4159.2007.04828.x.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L996</ref-id>
        <title>PFIZER RECEIVES FDA FAST TRACK DESIGNATION FOR TAFAMIDIS FOR TRANSTHYRETIN CARDIOMYOPATHY</title>
        <url>http://www.pfizer.com/news/press-release/press-release-detail/pfizer_receives_fda_fast_track_designation_for_tafamidis_for_transthyretin_cardiomyopathy</url>
      </link>
      <link>
        <ref-id>L6247</ref-id>
        <title>Tafamadis SmPC EMA</title>
        <url>https://www.ema.europa.eu/en/documents/product-information/vyndaqel-epar-product-information_en.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>**Indicated** for:&#13;
&#13;
1) The treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment in Europe.[L6247] &#13;
&#13;
2) The treatment of cardiomyopathy in wild type or hereditary transthyretin-mediated amyloidosis in the US.[label]&#13;
&#13;
There is a distinction in dosage between tafamidis, dosed at 61mg daily, and tafamadis meglumine which is dosed at 80mg daily.</indication>
  <pharmacodynamics>Transthyretin (TTR), also referred to as prealbumin, is an endogenous, soluble, beta-sheet rich, 127-amino acid, non-glycosylated protein that is largely synthesized and secreted into the blood flow by the liver [A27206]. This TTR circulates in the blood flow primarily in a tetramer configuration with only a very small amount of dissociated monomer [A27206]. In the blood, TTR tetramer main functions generally revolve around binding retinol-binding protein bound to retinol (holo-retinol-binding protein) and a small amount of thyroxine, followed by transporting these substances to tissues [A27206]. TTR tetramer consequently possesses two distinct dimer-dimer interfaces, the less stable of which comprises two highly conserved thyroxine binding sites [A27206]. Despite possessing the ability to bind and transport thyroxine, less than 10% of the thyroxine in blood is bound to TTR, leaving more than 99% of the thyroxine binding sites in TTR unbound [A27206].&#13;
&#13;
Tafamidis is consequently a rationally designed, non-NSAID benzoxazole derivative that specifically binds with high affinity and selectivity to the two typically vacant thyroxine binding sites on the native tetrameric form of TTR and functions to kinetically stabilize the tetramer, slowing monomer formation, misfolding, and amyloidogenesis [A27206]. Given this rational design, tafamidis demonstrates effective target specificity, resulting in a low-toxicity profile and good patient tolerance [A27206].&#13;
&#13;
Nevertheless, TTR dissociation into monomers in TTR familial amyloid polyneuropathy (TTR-FAP) is a progressive illness, a condition whose worsening can only be slowed - and not cured - by tafamidis therapy. The only formal treatment that can halt the progress of TTR-FAP is a liver transplant. General complications associated with transplant surgery including the inherent possibility for complications arising either during or as a result of the transplant procedure as well as the subsequent need for successful transplant patients to take various immune system suppressants to prevent long-term transplant organ rejection contribute to the natural risk associated with a liver transplant.</pharmacodynamics>
  <mechanism-of-action>Transthyretin (TTR) amyloid polyneuropathy (also known as TTR familial amyloid polyneuropathy, TTR-FAP) results from genetic mutations in the TTR gene that cause destabilization of ordinary TTR tetramers and/or speed up TTR tetramer dissociation into monomers [A27206]. TTR-FAP itself is a multi-faceted, progressive, axonal degenerative neuropathy characterized by sensory, motor, and autonomic impairment [FDA Label].&#13;
&#13;
The dissociation of TTR tetramers to monomers is, in fact, the rate-limiting step in the pathogenesis of TTR-FAP [FDA Label]. The folded monomers that comprise ordinary TTR tetramers undergo partial denaturation to produce alternatively folded monomeric amyloidogenic intermediates [FDA Label]. These intermediates then misassemble into a variety of soluble oligomers, profilaments, filaments, and amyloid fibrils [FDA Label]. These various undesired, soluble aggregates subsequently deposit upon tissues where they ultimately are not expected to be present or needed [A27206]. In particular, studies demonstrating TTR's ability to influence nerve physiology by enhancing nerve regeneration in mouse models [A32598] emphasizes a potential function of TTR for nerve biology and repair that may assist in explaining why mutant TTR aggregrates preferentially deposit in the peripheral nervous system of patients with TTR-FAP [A27206].&#13;
&#13;
Tafamidis is subsequently a rationally designed pharmaceutical that specifically binds non-cooperatively to the two thyroxine binding sites on the native tetrameric form of TTR to prevent its dissociation into monomers [FDA Label]. Tafamidis is consequently formally considered to be a specific stabilizer of TTR, and its inhibition of TTR tetramer dissociation forms the rationale for its use as a treatment to slow - but not cure - the disease progression of TTR-FAP [FDA Label].</mechanism-of-action>
  <toxicity>The most common adverse effects associated with taking tafamidis include urinary tract infection, vaginal infection, diarrhea, and upper abdominal pain [FDA Label].&#13;
&#13;
No cases of acute overdose have yet been reported [FDA Label]. In clinical trials of healthy volunteers, the highest dose of tafamidis administrated was 480 mg in a single dose and 60 mg once daily for two weeks [FDA Label]. The reported treatment-related adverse events were mild to moderate and included headache, somnolence, myalgia, insomnia, hordeolum, photosensitivity reaction, and presyncope [FDA Label].</toxicity>
  <metabolism>Based on preclinical data, it is believed that tafamidis is primarily metabolized by glucuronidation and then excreted by way of the bile [FDA Label].</metabolism>
  <absorption>After oral administration of tafamidis soft capsule, the maximum plasma concentration (Cmax) is achieved at a median time (tmax) of 2 hours after dosing in the fasted state [FDA Label]. Concomitant administration of food decreased the rate of absorption, but not the extent of absorption [FDA Label]. These results support the administration of tafamidis with or without food [FDA Label].</absorption>
  <half-life>After daily administration of a 20mg tafamidis dose for fourteen days in healthy subjects, the mean steady-state half-life observed was 59 hours [FDA Label].</half-life>
  <protein-binding>Tafamidis is highly protein bound at 99.9% in plasma [FDA Label].</protein-binding>
  <route-of-elimination>In humans, about 59% of a total administered dose of tafamidis is recovered in the feces, and approximately 22% of the dose is recovered in the urine [FDA Label].</route-of-elimination>
  <volume-of-distribution>The apparent steady-state volume of distribution is reported to be 25.7 liters [FDA Label].</volume-of-distribution>
  <clearance>After daily administration of a 20mg tafamidis dose for fourteen days in healthy subjects, the mean total clearance observed was 0.42 L/h [FDA Label].</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as phenyl-1,3-oxazoles. These are aromatic heterocyclic compounds containing a 1,3-oxazole substituted at one or more positions by a phenyl group.</description>
    <direct-parent>Phenyl-1,3-oxazoles</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Azoles</class>
    <subclass>Oxazoles</subclass>
    <alternative-parent>Aryl chlorides</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Benzoxazoles</alternative-parent>
    <alternative-parent>Carboxylic acids</alternative-parent>
    <alternative-parent>Dichlorobenzenes</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Monocarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organochlorides</alternative-parent>
    <alternative-parent>Organonitrogen compounds</alternative-parent>
    <alternative-parent>Organooxygen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Oxacyclic compounds</alternative-parent>
    <substituent>1,3-dichlorobenzene</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Aryl chloride</substituent>
    <substituent>Aryl halide</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Benzoxazole</substituent>
    <substituent>Carboxylic acid</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Chlorobenzene</substituent>
    <substituent>Halobenzene</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Monocarboxylic acid or derivatives</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organochloride</substituent>
    <substituent>Organohalogen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Oxacycle</substituent>
    <substituent>Phenyl-1,3-oxazole</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT002673</drugbank-id>
      <name>Tafamidis meglumine</name>
      <unii>ZU7CF08A1A</unii>
      <cas-number>951395-08-7</cas-number>
      <inchikey>DQJDBUPLRMRBAB-WZTVWXICSA-N</inchikey>
      <average-mass>503.33</average-mass>
      <monoisotopic-mass>502.0909711</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english/spanish/french" coder="inn/usan">Tafamidis</synonym>
    <synonym language="latin" coder="inn">Tafamidisum</synonym>
  </synonyms>
  <products>
    <product>
      <name>Vyndamax</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0069-8730</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>61 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA212161</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vyndaqel</name>
      <labeller>Pfizer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002294</ema-product-code>
      <ema-ma-number>EU/1/11/717/001</ema-ma-number>
      <started-marketing-on>2011-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Vyndaqel</name>
      <labeller>Pfizer</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002294</ema-product-code>
      <ema-ma-number>EU/1/11/717/002</ema-ma-number>
      <started-marketing-on>2011-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Vyndaqel</name>
      <labeller>Pfizer Laboratories Div Pfizer Inc</labeller>
      <ndc-id/>
      <ndc-product-code>0069-1975</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, liquid filled</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA211996</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Vyndaqel</name>
      <labeller>Pfizer Labs Division of Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0069-8729</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Vyndaqel</name>
      <ingredients>Tafamidis</ingredients>
    </mixture>
    <mixture>
      <name>Vyndaqel</name>
      <ingredients>Tafamidis</ingredients>
    </mixture>
    <mixture>
      <name>Vyndaqel</name>
      <ingredients>Tafamidis</ingredients>
    </mixture>
    <mixture>
      <name>Vyndaqel</name>
      <ingredients>Tafamidis</ingredients>
    </mixture>
    <mixture>
      <name>Vyndamax</name>
      <ingredients>Tafamidis</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Anti-Inflammatory Agents</category>
      <mesh-id>D000893</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A Inducers</category>
      <mesh-id>D065701</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A4 Inducers</category>
      <mesh-id>D065701</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A5 Inducers</category>
      <mesh-id>D065701</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 Enzyme Inducers</category>
      <mesh-id>D065693</mesh-id>
    </category>
    <category>
      <category>Fused-Ring Compounds</category>
      <mesh-id>D000072473</mesh-id>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>Hormones</category>
      <mesh-id>D006728</mesh-id>
    </category>
    <category>
      <category>Hormones, Hormone Substitutes, and Hormone Antagonists</category>
      <mesh-id>D006730</mesh-id>
    </category>
    <category>
      <category>Immunologic Factors</category>
      <mesh-id>D007155</mesh-id>
    </category>
    <category>
      <category>Nervous System</category>
      <mesh-id>D009420</mesh-id>
    </category>
    <category>
      <category>Pregnadienes</category>
      <mesh-id>D011245</mesh-id>
    </category>
    <category>
      <category>Pregnanes</category>
      <mesh-id>D011278</mesh-id>
    </category>
    <category>
      <category>Steroids</category>
      <mesh-id>D013256</mesh-id>
    </category>
    <category>
      <category>Steroids, Fluorinated</category>
      <mesh-id>D013259</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Capsule, liquid filled</form>
      <route>Oral</route>
      <strength>61 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>20 mg</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>20 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, liquid filled</form>
      <route>Oral</route>
      <strength>20 mg/1</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="N07XX08">
      <level code="N07XX">Other nervous system drugs</level>
      <level code="N07X">OTHER NERVOUS SYSTEM DRUGS</level>
      <level code="N07">OTHER NERVOUS SYSTEM DRUGS</level>
      <level code="N">NERVOUS SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>3tct</pdb-entry>
    <pdb-entry>4his</pdb-entry>
    <pdb-entry>6e6z</pdb-entry>
    <pdb-entry>6e72</pdb-entry>
    <pdb-entry>6e74</pdb-entry>
    <pdb-entry>6e77</pdb-entry>
    <pdb-entry>6fft</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB11644.pdf?1557506070</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB11644.pdf?1524001232</msds>
  <patents>
    <patent>
      <number>7214696</number>
      <country>United States</country>
      <approved>2007-05-08</approved>
      <expires>2023-12-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9770441</number>
      <country>United States</country>
      <approved>2017-09-26</approved>
      <expires>2035-08-31</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8653119</number>
      <country>United States</country>
      <approved>2014-02-18</approved>
      <expires>2024-01-28</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7214695</number>
      <country>United States</country>
      <approved>2007-05-08</approved>
      <expires>2024-04-27</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8168663</number>
      <country>United States</country>
      <approved>2012-05-01</approved>
      <expires>2023-12-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>3.91</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>3.23e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>4.21</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>darolutamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>308.116</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>306.980298509</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>OC(=O)C1=CC=C2N=C(OC2=C1)C1=CC(Cl)=CC(Cl)=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C14H7Cl2NO3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C14H7Cl2NO3/c15-9-3-8(4-10(16)6-9)13-17-11-2-1-7(14(18)19)5-12(11)20-13/h1-6H,(H,18,19)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>TXEIIPDJKFWEEC-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>63.33</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>84.69</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>29.74</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>3.6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-0.4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>78538</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>11001318</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347828016</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D09673</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>9176510</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50197883</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>3MI</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Tafamidis</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2103837</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB11644</drugbank-id>
        <name>Tafamidis</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02054</drugbank-id>
        <name>Tafamidis Acylglucuronide metabolite</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0003538</drugbank-id>
          <name>UDP-glucuronosyltransferase 1-9</name>
          <uniprot-id>O60656</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0003541</drugbank-id>
          <name>UDP-glucuronosyltransferase 1-1</name>
          <uniprot-id>P22309</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0003677</drugbank-id>
          <name>UDP-glucuronosyltransferase 1-3</name>
          <uniprot-id>P35503</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0004694</drugbank-id>
          <name>UDP-glucuronosyltransferase 1-6</name>
          <uniprot-id>P19224</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0004695</drugbank-id>
          <name>UDP-glucuronosyltransferase 1-7</name>
          <uniprot-id>Q9HAW7</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0003682</drugbank-id>
          <name>UDP-glucuronosyltransferase 1-8</name>
          <uniprot-id>Q9HAW9</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0003679</drugbank-id>
          <name>UDP-glucuronosyltransferase 2B7</name>
          <uniprot-id>P16662</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
  </reactions>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000337</id>
      <name>Transthyretin</name>
      <organism>Humans</organism>
      <actions>
        <action>chaperone</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P02766" source="Swiss-Prot">
        <name>Transthyretin</name>
        <general-function>Identical protein binding</general-function>
        <specific-function>Thyroid hormone-binding protein. Probably transports thyroxine from the bloodstream to the brain.</specific-function>
        <gene-name>TTR</gene-name>
        <locus>18q12.1</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-20</signal-regions>
        <theoretical-pi>5.58</theoretical-pi>
        <molecular-weight>15886.88</molecular-weight>
        <chromosome-location>18</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:12405</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>TTR</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>K02091</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>189582</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2851</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P02766</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>TTHY_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ATTR</synonym>
          <synonym>PALB</synonym>
          <synonym>Prealbumin</synonym>
          <synonym>TBPA</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010252|Transthyretin
MASHRLLLLCLAGLVFVSEAGPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDT
WEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDS
GPRRYTIAALLSPYSYSTTAVVTNPKE</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010253|Transthyretin (TTR)
ATGGCTTCTCATCGTCTGCTCCTCCTCTGCCTTGCTGGACTGGTATTTGTGTCTGAGGCT
GGCCCTACGGGCACCGGTGAATCCAAGTGTCCTCTGATGGTCAAAGTTCTAGATGCTGTC
CGAGGCAGTCCTGCCATCAATGTGGCCGTGCATGTGTTCAGAAAGGCTGCTGATGACACC
TGGGAGCCATTTGCCTCTGGGAAAACCAGTGAGTCTGGAGAGCTGCATGGGCTCACAACT
GAGGAGGAATTTGTAGAAGGGATATACAAAGTGGAAATAGACACCAAATCTTACTGGAAG
GCACTTGGCATCTCCCCATTCCATGAGCATGCAGAGGTGGTATTCACAGCCAACGACTCC
GGCCCCCGCCGCTACACCATTGCCGCCCTGCTGAGCCCCTACTCCTATTCCACCACGGCT
GTCGTCACCAATCCCAAGGAATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00576</identifier>
            <name>Transthyretin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>hormone binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>extracellular matrix organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phototransduction, visible light</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retinoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retinol metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>